Monoamine Transporters: Vulnerable and Vital Doorkeepers
Transporters of dopamine, serotonin, and norepinephrine have been empirically used as medication targets for several mental illnesses in the last decades. These protein-targeted medications are effective only for subpopulations of patients with transporter-related brain disorders. Since the cDNA clo...
Saved in:
Published in | Progress in molecular biology and translational science Vol. 98; pp. 1 - 46 |
---|---|
Main Authors | , , , , , , , |
Format | Book Chapter Journal Article |
Language | English |
Published |
United States
Elsevier Science & Technology
2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Transporters of dopamine, serotonin, and norepinephrine have been empirically used as medication targets for several mental illnesses in the last decades. These protein-targeted medications are effective only for subpopulations of patients with transporter-related brain disorders. Since the cDNA clonings in early 1990s, molecular studies of these transporters have revealed a wealth of information about the transporters' structure-activity relationship (SAR), neuropharmacology, cell biology, biochemistry, pharmacogenetics, and the diseases related to the human genes encoding these transporters among related regulators. Such new information creates a unique opportunity to develop transporter-specific medications based on SAR, mRNA, DNA, and perhaps transporter trafficking regulation for a number of highly relevant diseases including substance abuse, depression, schizophrenia, and Parkinson's disease. |
---|---|
ISBN: | 0123855063 9780123855060 |
ISSN: | 1877-1173 1878-0814 |
DOI: | 10.1016/B978-0-12-385506-0.00001-6 |